Lin H, Li S-N, Bai R, Wen S-N, Liu N, Long D-Y, Yu R-H, Tang R-B, Sang C-H, Du X, Dong J-Z, Ma C-S
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Beijing Anzhen Road, Chaoyang District, 100029, Beijing, China.
Herz. 2018 Mar;43(2):169-176. doi: 10.1007/s00059-017-4551-8. Epub 2017 Mar 17.
The safety of anticoagulation and radiofrequency catheter ablation (RFCA) in patients with atrial fibrillation (AF) and a history of intracranial hemorrhage (ICH) remains unclear. We investigated the risks and benefits of this approach in AF patients with a history of ICH.
The ICH group included 45 AF patients with a history of ICH who underwent RFCA. Five of these patients were excluded because ICH occurred spontaneously after cerebral infarction. The control group included 80 individuals who presented for AF ablation and did not have a history of ICH. Two controls were matched for each study group patient in terms of sex, age (±2 years), type of AF, and procedure date.
Patients in the ICH group had higher CHADS (1.7 ± 1.3 vs. 1.1 ± 1.2, p < 0.05), CHADS-VASc (2.6 ± 1.7 vs. 1.9 ± 1.6, p < 0.05), and HAS-BLED scores (2.5 ± 1.0 vs. 1.1 ± 1.0, p < 0.001). All participants in both groups underwent successful RFCA. The incidence of ICH during follow-up (1 vs. 0, p = 0.333) was similar between the ICH and control groups. AF-free survival between the two groups was not significant (log-rank p = 0.283) within the first 3 months, but was significant (log-rank p = 0.011) within 48 months of RFCA. History of ICH was the only independent predictor of AF recurrence according to univariate Cox regression analysis.
In AF patients with a history of ICH, AF ablation with a standard anticoagulation strategy is safe and does not seem to be associated with an increased risk of hemorrhage.
房颤(AF)合并颅内出血(ICH)病史患者的抗凝治疗及射频导管消融(RFCA)安全性尚不清楚。我们调查了这种治疗方法在有ICH病史的AF患者中的风险和益处。
ICH组包括45例有ICH病史并接受RFCA的AF患者。其中5例患者因脑梗死后自发性ICH被排除。对照组包括80例因AF消融就诊且无ICH病史的个体。根据性别、年龄(±2岁)、房颤类型和手术日期,为每个研究组患者匹配两名对照。
ICH组患者的CHADS评分(1.7±1.3 vs. 1.1±1.2,p<0.05)、CHADS-VASc评分(2.6±1.7 vs. 1.9±1.6,p<0.05)和HAS-BLED评分(2.5±1.0 vs. 1.1±1.0,p<0.001)更高。两组所有参与者的RFCA均成功。ICH组和对照组随访期间ICH发生率相似(1例 vs. 0例,p=0.333)。两组间无房颤生存期在前3个月无显著差异(对数秩检验p=0.283),但在RFCA后48个月有显著差异(对数秩检验p=0.011)。根据单因素Cox回归分析,ICH病史是房颤复发的唯一独立预测因素。
对于有ICH病史的AF患者,采用标准抗凝策略进行房颤消融是安全的,且似乎与出血风险增加无关。